



**Office of Vermont Health Access
Pharmacy Benefits Management Program
DUR Board Meeting Agenda**

October 13, 2009 6:30 – 9:00 p.m.

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**
(Public Comment Prior to Board Action)

- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**

- 4. Medical Director Update** **7:15 - 7:20**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meeting** **7:20 - 7:25**
 - Kapidex[®] Communications
 - Vectical[®] (calcitriol) Topical Ointment

- 6. Clinical Update: Drug Reviews** **7:20 – 8:00**
(Public comment prior to Board action)
 - Abbreviated New Drug Reviews**
 - Aplenzin[®] (bupropion extended release) Tablet
 - Full New Drug Reviews**
 - Rapaflo[®] (silodosin) Capsule
 - Simponi[®] (golimumab) Prefilled Injection
 - Toviaz[®] (fesoterodine) ER Tablet

- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **8:00 – 8:10**
(Public comment prior to Board action)
 - Influenza Medications
 - Ossification Enhancers

- 8. Drug Classes – Annual Review** **8:10 – 8:40**
(Public comment prior to Board action)
 - Class review documents available on OVHA web site 10/13/09 @ 12 Noon**
 - Bisphosphonates
 - Calcitonins
 - Parathyroid Hormones

- 9. RetroDUR** **8:40 - 8:50**
 - Cough and Cold Products in Children Less than 2 years old
 - Future Topics?

- 10. New Drug Product Plan Exclusions (Consent Agenda Topic)** **8:50 - 8:50**

- 11. Updated New-to-Market Drug Monitoring Log (Consent Agenda Topic) 8:50 - 8:50**
- Now on OVHA website
- 12. General Announcements 8:50 – 8:55**
- Selected FDA Safety Alerts**
- Sitagliptin - pancreatitis
 - Tysabri[®] – more cases of PML
- 13. Adjourn 9:00**